依奇珠单抗：HIV 阳性银屑病患者的另一种选择。
Ixekizumab: an alternative for HIV-positive psoriasis patients.
机构信息
Department of Dermatology, Ganzhou Municipal Hospital, Ganzhou, Jiangxi Province, 341000, People's Republic of China.
Department of Dermatology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, No.106, Zhongshan Second Road, Guangzhou, Guangdong Province, 510080, People's Republic of China.
出版信息
AIDS Res Ther. 2024 Nov 28;21(1):87. doi: 10.1186/s12981-024-00675-8.
Psoriasis is a recurrent and protracted inflammatory disease. Generalized erythema, plaques, and silvery scales on the surface mainly characterize its skin lesions. Biologics bring new hope to psoriasis patients. However, HIV infection is a major concern before receiving biologics. Here, we present a case of the efficacy and safety of Ixekizumab, an interleukin 17 inhibitor, in the treatment of psoriasis patients living with HIV (PPLHIV).
银屑病是一种反复发作且病程迁延的炎症性疾病。其皮损的主要特征是皮肤表面出现广泛红斑、斑块和银白色鳞屑。生物制剂为银屑病患者带来了新的希望。然而，在接受生物制剂治疗前，HIV 感染是一个主要关注点。在此，我们报告了一例使用白细胞介素 17 抑制剂依奇珠单抗治疗 HIV 阳性银屑病患者（PPLHIV）的疗效和安全性。
Zotero 插件